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Oleg А. Zemlyanski1*, Еlena B. Turina1,2, Еlena V. Kaliuzhnaya1, Alina M. Bronnikova1
INTRODUCTION
The World Health Organization (WHO) notes that 
tuberculosis (TB) remains the most deadly infectious 
disease in the world today. In 2017, 10 million people 
became infected with TB, and for 1.6 million more, it 
was the cause of death.[1]
WHO confirms that the problem of multidrug-resistant 
TB has not been resolved yet. Annually in the world, 
580 thousand patients fall ill with multidrug-resistant 
TB, a characteristic feature of which is high mortality. 
The risk of a patient with multidrug resistance to die 
from TB is at least 40%.
Among patients with multidrug-resistant TB, about 
9–10% of patients with extensive drug resistant have 
been identified, which adversely affects the outcome 
of treatment.[2]
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The spread of drug-resistant TB indicates a low 
efficacy of anti-epidemic measures, including a lack 
of control over the use of anti-TB drugs.[3,4]
The Russian Federation is among the countries with 
the largest number of multidrug-resistant TB, which is 
caused by both the relatively high incidence of TB and 
the high proportion of drug resistance among patients.[5,6]
Until now, the Russian Federation has not included 
extensive drug-resistant TB in the accounting and 
reporting forms of the national statistical system; 
therefore, representative information on the spread of 
extensive drug-resistant TB is available only for a few 
Russian subjects, where selective studies were conducted 
or regional monitoring systems were functioning.[7]
In the Belgorod region, there is a regional system of 
routine epidemiological monitoring, which provides 
for the collection of data on bacterial excretion and 
resistance to anti-TB drugs for all patients.[8,9]
The Belgorod region is characterized by a prosperous 
epidemiological situation with respect to TB. For 
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the analyzed period, the incidence rate decreased 
by 70.0%, from 57.0 to 17.1/100 thousand of the 
population; mortality rate decreased by 80.8%, from 
5.2 in 2008 up to 1.0/100 thousand population in 
2017.
However, the proportion of patients with multidrug 
resistance does not decrease. On the contrary, this 
indicator increased among newly diagnosed patients 
from 22.0 to 29.3%; and among relapses, it remained 
at a high level and amounted to 72.4% in 2017.[10,11]
The above dictates the urgent need to analyze the 
structure and development trends of drug resistance of 
the TB pathogen in the Belgorod region.
MATERIALS AND METHODS
Based on the materials of the Belgorod Oblast TB 
Dispensary (statistical accounting forms 07-TB) and 
the centralized bacteriological laboratory, an analysis 
of the structure and dynamics of Mycobacterium 
tuberculosis resistance to the first line or main anti-
TB drugs (isoniazid, rifampicin, streptomycin, and 
ethambutol) and the second row was carried out-
reserve (kanamycin, ofloxacin, and capreomycin). 
Data on the drug resistance of M. tuberculosis 
strains isolated from all bacterial-excreting patients 
before chemotherapy for 2008–2017 were available 
for analysis, which made it possible to evaluate the 
structure and trends in drug resistance over a 10-year 
period.
Drug resistance of the causative agent of TB in patients 
was determined on the strains obtained at the stage of 
diagnostics before the start of treatment and selected 
according to the principle “one patient-one strain.” 
The methods of determination were the methods of 
absolute concentrations on a Levenshtein-Jensen 
medium and proportions on a liquid medium in the 
ВАСТЕС MGIT 960 system.
The Aim of the Study
The aim of the study was to evaluate and compare 
the structure and dynamics of drug resistance of 
M. tuberculosis to anti-TB drugs, including multiple 
and broad, in the Belgorod region in newly diagnosed 
patients and patients with relapses of TB over the 
10-year period of 2008–2017.
RESULTS
During the analyzed period, patients with newly 
diagnosed TB experienced a general increase in the 
resistance of the pathogen to all drugs [Table 1].
The highest indicator of drug resistance of the 
pathogen is marked to streptomycin – a drug that has 
been used in the treatment of TB for 70 years. For the 
years analyzed, resistance to streptomycin increased 
almost constantly and increased by 16.9% from 39.6 
to 46.3% by the end of the 10-year period.
Resistance to two main first-line drugs, isoniazid and 
rifampicin, showed a similar trend. Isoniazid resistance 
increased by 24.6–41.0%, rifampicin – by 31.4% 
and amounted to 29.3% in 2017. The resistance to 
ethambutol increased by 28.2% and amounted to 19.1%.
As for the second-line drugs, their resistance at 
the beginning of the analyzed period was very low, 
but by 2017, the rates increased several times and 
amounted to 7.4% for kanamycin, ofloxacin, and 
capreomycin – by 4.3% each.
In patients with recurrent TB, drug resistance rates 
significantly exceed those in newly diagnosed patients 
[Table 2].
Indicators of resistance to the first-line drugs in patients 
with relapses by the end of the 10-year period were as 
follows: To isoniazid, 72.4%, which is 76.6% higher 
than in newly diagnosed patients; to rifampicin – 72.4% 
(2.5 times higher); to streptomycin – 75.9% (up 63.9%); 
Table 1: Drug resistance of Mycobacterium tuberculosis in patients with newly diagnosed tuberculosis, 
2008–2017 (%)
A drug 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Isoniazid 32.9 32.9 35.3 36.2 38.9 40.8 44.9 33.3 38.1 41.0
Rifampicin 22.3 20.2 18.5 20.5 24.9 22.5 28.3 23.3 27.5 29.3
Streptomycin 39.6 38.3 38.7 39.1 43.8 42.3 43.9 36.5 40.7 46.3
Ethambutol 14.9 17.5 15.7 15.7 19.4 18.3 22.9 17.8 20.1 19.1
Kanamycin 2.7 3.2 2.6 4.5 4.2 3.3 5.4 4.1 7.4 7.4
Ofloxacin 1.7 1.9 0.6 1.6 1.7 2.8 1.0 2.3 5.8 4.3
Capreomycin 0.5 1.3 0.9 2.9 2.4 1.9 2.0 1.4 2.1 4.3
Table 2: Drug resistance of Mycobacterium tuberculosis in patients with recurrent tuberculosis, 2008‑2017 (%)
A drug 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Isoniazid 80.4 61.3 71.8 74.0 73.1 60.0 71.0 55.6 71.4 72.4
Rifampicin 72.9 53.8 56.3 64.9 65.7 48.0 66.1 47.2 71.4 72.4
Streptomycin 78.5 67.7 71.8 75.3 73.1 60.0 74.2 63.9 64.3 75.9
Ethambutol 60.3 48.4 42.3 49.4 44.8 44.0 37.1 47.2 53.6 58.6
Kanamycin 22.9 14.0 14.1 28.6 7.5 10.0 21.0 5.6 17.9 31.0
Ofloxacin 15.0 8.6 5.6 10.4 7.5 8.0 12.9 16.7 21.4 20.7
Capreomycin 8.4 6.5 5.6 15.6 3.0 6.0 3.2 2.8 7.1 10.3
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and to ethambutol – 58.6% (3.1 times higher than in 
newly diagnosed patients). However, during the years 
analyzed, the figures varied with a certain tendency to 
decrease. Thus, resistance to streptomycin decreased by 
3.3%, to isoniazid – by 10.0%, to rifampicin – by 0.7%, 
and to combutol – by 2.8%.
In contrast, indicators of resistance to the second-line 
drugs increased. Resistance to kanamycin increased by 
35.4% and amounted to 31.0%, of ofloxacin – by 38.0% 
and amounted to 20.7% in 2017. The index of resistance 
to capreomycin increased by 22.6% and amounted 
to 10.3%. All these indicators are higher than those 
in newly diagnosed patients: kanamycin – 4.2 times, 
ofloxacin – 4.8 times, and capreomycin – 2.4 times.
We analyzed the tendency of changes in the indicators 
of multidrug resistance of the TB pathogen in both 
newly diagnosed patients and in patients with relapses 
[Figure 1].
During the analyzed period, the indicator of multidrug 
resistance in newly diagnosed patients varied with a 
tendency to increase, increased by 33.1% by 2017 and 
amounted to 29.3%.
In patients with recurrent TB, the indicator of 
multidrug resistance of the pathogen is much higher. 
In 2017, it was 72.4%, which is 2.5 times higher than 
the rate of newly diagnosed patients.
It is worth noting that the indicator of multidrug resistance 
in relapses practically did not change in 10 years. This 
fact, as well as some tendency to reduce the resistance 
to the first-line drugs in patients with relapses, may be 
related to the implementation in 2008–2010 of the Green 
Light Committee project on the treatment of patients 
with multidrug-resistant patients. During this project, a 
significant number of such patients were treated with a 
2-year course of chemotherapy with high-quality drugs, 
which could change the structure and slow down the 
increase in drug resistance in patients with relapses.
At present, there is an alarming trend toward the 
growth of broad drug resistance of strains isolated 
from various categories of patients [Figure 2].
Figure 1: The dynamics of multidrug resistance Mycobacterium tuberculosis, 2008–2017 (% of all strains isolated)
Figure 2: Dynamics of extensive drug resistance Mycobacterium tuberculosis, 2008–2017 (% of all multidrug-resistant strains)
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Despite the singularity of the cases of TB with 
extensive drug resistance, their proportion among 
newly diagnosed patients increased almost 7 times, 
from 1.3 to 9.1%, among relapses – 3.4 times, from 
7.0% to 23.8 %, which is an extremely unfavorable 
sign.
CONCLUSIONS
In the 10-year period 2008–2017, in the Belgorod 
region, patients with newly diagnosed TB showed a 
general increase in the resistance of the pathogen to 
anti-TB drugs. The highest indicator of drug resistance 
of the pathogen is marked to streptomycin. Resistance 
to other main and reserve drugs increased almost 
constantly.
In patients with relapses, although significantly 
higher rates of drug resistance are observed than in 
those newly diagnosed, there was a slight decrease in 
drug resistance in the 2008–2017 period. In contrast, 
the indicators of resistance to the second-line drugs 
increased.
The rate of multidrug resistance in newly diagnosed 
patients increased by 33.1% by 2017. In relapses, it 
did not practically change in 10 years. This fact, as 
well as the reduction in resistance to the first-line 
drugs in patients with relapses, may be related to the 
implementation in 2008–2010 of the Green Light 
Committee project in the region.
There is an alarming tendency in the region to 
increase the wide drug resistance of strains isolated 
from various categories of patients, which is an 
extremely unfavorable sign, significantly complicates 
the appointment of adequate therapy to patients and 
reduces the effectiveness of treatment.
Thus, over the study period in the Belgorod 
region, against the background of a successful TB 
epidemiological situation, a steady decline in morbidity 
and mortality, there is an increase in the indicators of 
drug resistance of M. tuberculosis, including multiple 
and widespread resistance.
All of the above emphasize the importance of 
monitoring the drug resistance of M. tuberculosis, 
which is an integral part of controlling the spread of 
this infectious disease. It is necessary to continue this 
work, which will make it possible to predict the risk 
of spreading drug-resistant TB and differentiate the 
approach to anti-epidemic measures in the Belgorod 
region.
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